This clinical trial seeks to improve the effects of mySmartSkin (MSS) and proactively identify barriers and facilitators in follow up care for melanoma survivors. MSS is a fully-automated, interactive, tailored intervention that provides information about melanoma, skin cancer risk factors, how to do skin self-examinations, tailored assessments of current behaviors, and planning behavioral change. mySmartSkin may help doctors improve skin self-examination in melanoma survivors.
Additional locations may be listed on ClinicalTrials.gov for NCT05373823.
Locations matching your search criteria
United States
New Jersey
New Brunswick
Rutgers Cancer Institute of New JerseyStatus: Active
Contact: Sharon Manne
Phone: 732-235-6759
PRIMARY OBJECTIVES:
I. To enhance mySmartSkin (MSS) by collaborating with multi-level stakeholders.
II. To evaluate the effects of enhanced MSS on thorough skin self-examination (SSE) in an randomized controlled trial (RCT) and examine its impact on the diagnosis of new/recurrent melanomas (N= 300).
III. To assess selected implementation outcomes and identify factors relevant to future scale-up for widespread dissemination and implementation.
IIIa.To estimate program costs and assess cost-effectiveness of MSS relative to control.
IIIb. To examine MSS’ reach, adoption, engagement, acceptability, appropriateness, feasibility, and maintenance.
IIIc. To identify and describe contextual factors from multilevel stakeholders as key to scale-up and widespread implementation of MSS, including consideration of potential delivery settings, timing of delivery, and needed resources to promote its implementation and sustainability.
OUTLINE:
AIM I (MSS Enhancement): Patients take part in key informant interviews.
AIM II: Participants are randomized to 1 of 2 arms
ARM I (Educational webpage): Patients view on-interactive educational webpage and complete surveys on study.
ARM II (comparison): Patients take part in key informant interviews on study.
AIM III: Patients complete surveys and take part in interviews.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationRutgers Cancer Institute of New Jersey
Principal InvestigatorSharon Manne